市販薬市場：製品別、流通チャネル別-2025-2030年の世界予測

市販薬市場は、2023年に4,641億4,000万米ドルと評価され、2024年には5,048億6,000万米ドルに達すると予測され、CAGR 8.86%で成長し、2030年には8,412億米ドルに達すると予測されています。

一般用医薬品（OTC）市場とは、処方箋なしで購入できる医薬品のことで、消費者が風邪や頭痛、アレルギーなどの軽度の病気に単独で対処できるようにするものです。OTC医薬品の必要性は、セルフメディケーションの需要が高まっていることと、ヘルスケア情報がオンラインで入手しやすくなり、消費者が十分な情報を得た上で健康上の決定を下せるようになったことに起因しています。OTC医薬品の主な用途には、鎮痛剤、胃腸治療、皮膚科、栄養補助食品などがあります。最終用途の範囲には、主にドラッグストア、スーパーマーケット、オンライン小売チャネルを通じた消費者の直接販売が含まれます。市場成長は、高齢化、小売薬局チェーンの拡大、ヘルスケアコスト削減のために処方薬をOTCに再分類する方向への規制シフトなどの要因に大きく影響されます。デジタルヘルスプラットフォームは、OTC医薬品への消費者のアクセスをさらに向上させ、市場プレーヤーにとって肥沃な土壌となります。持続可能性に対する需要の高まりに対応するため、副作用の少ない先進的な製剤や環境に優しいパッケージングの開発など、製品イノベーションに潜在的なビジネスチャンスがあります。市場は堅調な成長が見込まれるもの、さまざまな管轄区域における厳しい規制や、一般用医薬品の誤用・過剰使用のリスクなど、重大な課題に直面しています。また、特にジェネリック医薬品による激しい競争と価格圧力といった制約もあります。企業は、AIや機械学習を使って顧客データを分析し、オーダーメイドの製品を提供するパーソナライズドOTCソリューションなどの革新的な分野に注力することができます。さらに、遠隔医療サービスを統合することで、消費者の信頼と関与を高めることができます。市場の競争は激しいが、利便性、安全性、健康志向への消費者の嗜好の進化に後押しされたダイナミックな市場です。ベンダー主は、データ分析と戦略的パートナーシップを活用してこうした複雑な状況を乗り切り、規制規範への積極的なコンプライアンスを確保すると同時に、新たな動向を活用して市場のリーダーシップを維持することが強く求められています。

市場力学：急速に進化する市販薬市場の主要市場インサイトを公開

市販薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 軽度の健康問題を治療する費用対効果の高い方法
  • 医師の負担軽減
  • 有利な規制枠組み
• 市場抑制要因
  • 市場の飽和による代替薬の存在
• 市場機会
  • 小売店やスーパーマーケットを通じたアクセスの増加
  • 技術の進歩と製品の革新
• 市場の課題
  • 低価格維持への圧力

ポーターの5つの力：市販薬市場をナビゲートする戦略ツール

ポーターのファイブフォース（5つの力）は、市販薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：市販薬市場における外部からの影響の把握

外部マクロ環境要因は、市販薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析市販薬市場における競合情勢の把握

市販薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス市販薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、市販薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨市販薬市場における成功への道筋を描く

市販薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 軽度の健康問題を治療する費用対効果の高い方法
    • 医師の負担軽減
    • 好ましい規制枠組み
  • 抑制要因
    • 市場飽和による代替薬の存在
  • 機会
    • 小売店やスーパーマーケットを通じたアクセスの向上
    • 技術の進歩と製品の革新
  • 課題
    • 価格を低く抑える圧力
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 市販薬市場：製品別

• 鎮痛剤
• 咳止め、風邪、インフルエンザ対策製品
• 皮膚科製品
• 胃腸薬
• 眼科用製品
• 睡眠補助剤
• ビタミン、ミネラル、サプリメント
• 減量・ダイエット製品

第7章 市販薬市場：流通チャネル別

• 病院薬局
• オンラインストア
• 小売薬局

第8章 南北アメリカの市販薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の市販薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの市販薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alembic Pharmaceuticals Ltd.
• Alkem Laboratories Limited
• Cipla, Inc.
• Dr. Reddy's Laboratories
• Glaxosmithkline PLC
• Glenmark Pharmaceuticals Limited
• Hetero Drugs Ltd.
• Johnson & Johnson Pvt. Ltd.
• Lupin Limited
• Mankind Pharma
• Mylan Pharmaceuticals Pvt. Ltd. by Viatris
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. OVER THE COUNTER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. OVER THE COUNTER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OVER THE COUNTER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH, COLD, & FLU PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GASTROINTESTINAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OPHTHALMIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SLEEPING AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS, MINERAL, & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY WEIGHT-LOSS & DIETARY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 107. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Over The Counter Drugs Market was valued at USD 464.14 billion in 2023, expected to reach USD 504.86 billion in 2024, and is projected to grow at a CAGR of 8.86%, to USD 841.20 billion by 2030.

The Over-the-Counter (OTC) drugs market refers to pharmaceuticals that can be purchased without a prescription, allowing consumers to manage minor ailments such as colds, headaches, and allergies independently. The necessity of OTC drugs stems from the rising demand for self-medication and the increasing accessibility of healthcare information online, empowering consumers to make informed health decisions. Key applications of OTC drugs include pain relief, gastrointestinal treatments, dermatology, and dietary supplements. End-use scope primarily involves direct consumer sales through drugstores, supermarkets, and online retail channels. Market growth is significantly influenced by factors such as an aging population, the expansion of retail pharmacy chains, and regulatory shifts towards reclassifying prescription drugs as OTC to decrease healthcare costs. Digital health platforms further enhance consumer access to OTC medications, representing a fertile ground for market players. Potential opportunities lie in product innovation, such as developing advanced formulations with fewer side effects and eco-friendly packaging to meet the rising demand for sustainability. Despite robust growth prospects, the market faces significant challenges such as stringent regulations across varying jurisdictions and the risk of misuse or overuse of OTC products. Other limitations include intense competition and pricing pressures, especially from generic alternatives. Companies can focus on innovative areas such as personalized OTC solutions using AI and machine learning to analyze customer data for tailored product offerings. Additionally, integrating telehealth services can enrich consumer trust and engagement. The market's nature is highly competitive yet dynamic, driven by evolving consumer preferences towards convenience, safety, and health consciousness. Vendors are urged to leverage data analytics and strategic partnerships to navigate these complexities, ensuring proactive compliance with regulatory norms while capitalizing on emerging trends to sustain market leadership.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Over The Counter Drugs Market

The Over The Counter Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Cost effective way to treat minor health issues
  • Reduced burden of the physician
  • Favorable regulatory framework
• Market Restraints
  • Presence of substitute drug due to saturating market
• Market Opportunities
  • Increased accessibility through retail outlets and supermarkets
  • Technological advancement and product innovation
• Market Challenges
  • Pressure to keep the price low

Porter's Five Forces: A Strategic Tool for Navigating the Over The Counter Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Over The Counter Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Over The Counter Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Over The Counter Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Over The Counter Drugs Market

A detailed market share analysis in the Over The Counter Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Over The Counter Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Over The Counter Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Over The Counter Drugs Market

A strategic analysis of the Over The Counter Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Over The Counter Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Alkem Laboratories Limited, Cipla, Inc., Dr. Reddy's Laboratories, Glaxosmithkline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Ltd., Johnson & Johnson Pvt. Ltd., Lupin Limited, Mankind Pharma, Mylan Pharmaceuticals Pvt. Ltd. by Viatris, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Over The Counter Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Analgesics, Cough, Cold, & Flu Products, Dermatology Products, Gastrointestinal Products, Ophthalmic Products, Sleeping Aids, Vitamins, Mineral, & Supplements, and Weight-Loss & Dietary Products.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Cost effective way to treat minor health issues
    • 5.1.1.2. Reduced burden of the physician
    • 5.1.1.3. Favorable regulatory framework
  • 5.1.2. Restraints
    • 5.1.2.1. Presence of substitute drug due to saturating market
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased accessibility through retail outlets and supermarkets
    • 5.1.3.2. Technological advancement and product innovation
  • 5.1.4. Challenges
    • 5.1.4.1. Pressure to keep the price low
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Over The Counter Drugs Market, by Product

• 6.1. Introduction
• 6.2. Analgesics
• 6.3. Cough, Cold, & Flu Products
• 6.4. Dermatology Products
• 6.5. Gastrointestinal Products
• 6.6. Ophthalmic Products
• 6.7. Sleeping Aids
• 6.8. Vitamins, Mineral, & Supplements
• 6.9. Weight-Loss & Dietary Products

7. Over The Counter Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Stores
• 7.4. Retail Pharmacies

8. Americas Over The Counter Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Over The Counter Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Over The Counter Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals Ltd.
• 2. Alkem Laboratories Limited
• 3. Cipla, Inc.
• 4. Dr. Reddy's Laboratories
• 5. Glaxosmithkline PLC
• 6. Glenmark Pharmaceuticals Limited
• 7. Hetero Drugs Ltd.
• 8. Johnson & Johnson Pvt. Ltd.
• 9. Lupin Limited
• 10. Mankind Pharma
• 11. Mylan Pharmaceuticals Pvt. Ltd. by Viatris
• 12. Pfizer Inc.
• 13. Sanofi S.A.
• 14. Sun Pharmaceutical Industries Ltd.
• 15. Teva Pharmaceutical Industries Ltd.